Retraction Note to: Oncogene https://doi.org/10.1038/s41388-018-0459-x, published online 30 August 2018
The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding highly similar data in some of the figures, specifically:
-
Fig. 2A IGROV1 CR ERK blot appears highly similar to Fig. 6G PEO1, PEO4 ERK.
-
Fig. S2B Ctr+Cisplatin image appears highly similar to Fig. S3A siEZH2+Cisplatin.
The authors have requested a correction and provided the associated original data. However, further checks by the publisher found additional issues with the original data, as some blots presented in the article as phosphorylated and total proteins appear to originate from the same full-gel scans.
The Editors-in-Chief therefore no longer have confidence in the presented data.
Yan Kai, Alexandros Tzatsos, Weiqun Peng and Wenge Zhu agree with this retraction but not the wording of this retraction notice. Xin Cai disagrees with this retraction. The other authors did not respond to any correspondence from the Publisher about this retraction.
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Sun, J., Cai, X., Yung, M.M.H. et al. Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 45, 668 (2026). https://doi.org/10.1038/s41388-026-03676-1
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41388-026-03676-1